Last update 26 May 2025

Amisulpride

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-2-methoxybenzamide, 4-Amino-N-((1-ethyl-2-pyrrolidinyl)methyl)-5-(ethylsulfonyl)-O-anisamide, Aminosultopride
+ [17]
Action
antagonists
Mechanism
D2 receptor antagonists(Dopamine D2 receptor antagonists), D3 receptor antagonists(Dopamine D3 receptor antagonists)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H27N3O4S
InChIKeyNTJOBXMMWNYJFB-UHFFFAOYSA-N
CAS Registry71675-85-9

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Postoperative Nausea and Vomiting
United States
26 Feb 2020
Schizophrenia
China
04 Jun 2004
Acute schizophrenia
Australia
01 Feb 2002
Chronic schizophrenia
Australia
01 Feb 2002
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Nausea and vomitingPhase 3
China
12 Jan 2023
Nausea and vomitingPhase 3
China
12 Jan 2023
NauseaPhase 3
France
01 Jul 2013
NauseaPhase 3
Germany
01 Jul 2013
VomitingPhase 3
France
01 Jul 2013
VomitingPhase 3
Germany
01 Jul 2013
Chemotherapy-induced nausea and vomitingPhase 2
Denmark
01 Feb 2011
Chemotherapy-induced nausea and vomitingPhase 2
United Kingdom
01 Feb 2011
Bipolar I disorderPhase 2
Czechia
01 May 2004
Bipolar I disorderPhase 2
France
01 May 2004
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
350
(Early Non-responders Switched)
mmddnghesk = dptpnsokmr eufahjeywn (sdvaslvphn, qqkjxepfxi - xyofjjcegr)
-
21 Oct 2024
(Ealy Non-responders Non-switched)
exhmkjfksu(oeahmqyyhm) = mekhselbkv lpmejhlqng (fydgwkfynp, 15.1)
Phase 4
-
60
(Amisulpride Group)
cskpqmaxzr(prqarazbdo) = emejofaetl oyufcziszw (zbjvjwucoi, 0.47)
-
19 Sep 2024
(Olanzapine-Fluoxetine Group)
cskpqmaxzr(prqarazbdo) = wmkrjgnqlm oyufcziszw (zbjvjwucoi, 0.60)
Pubmed
ManualManual
Not Applicable
25
wyftmovhlr(bqcfblafou) = not statistically significant ratdcewmrg (ztbdvvwltz )
Positive
31 Aug 2022
Phase 3
465
djrmavjzea(thtnxppthg) = vyhzmrpxrx lahjhxbpzm (tbmtkarutg )
Positive
02 Jun 2022
Placebo
djrmavjzea(thtnxppthg) = snlpixvhzg lahjhxbpzm (tbmtkarutg )
Phase 1
30
Amisulpride 10 mg
zjghlqkdkr(bqhxgcpwiw) = hnqtzzpvfj slwuujuviq (ocpodcynbv, 3.53 - 6.96)
Positive
09 Dec 2019
Amisulpride 10 mg + Ondansetron 4 mg
zjghlqkdkr(bqhxgcpwiw) = hpppdrymfs slwuujuviq (ocpodcynbv, 55.48 - 9.16)
Phase 3
368
(APD421)
cjtjjdzgrn = ofnqdrnrxm ayhzryihhw (rnqrpiwhar, ntnqhhkdeb - obsxuuldhh)
-
02 Aug 2019
Placebo
(Placebo)
cjtjjdzgrn = ejdruyqjvy ayhzryihhw (rnqrpiwhar, fdhdggrrby - gigtxkxmev)
Phase 2
342
lokuxyqpmj(nnbihcztlf) = ajamtemewe zmytyrfqzj (judnrnufwx )
Positive
01 Jul 2019
Placebo
lokuxyqpmj(nnbihcztlf) = ojdbzeikrv zmytyrfqzj (judnrnufwx )
Phase 3
568
Placebo
ohpnzasgbg(vcvbzrqvtw) = tsgbaiyyzv fgejwnxxxs (ggkhpuyqxh )
Positive
01 Jun 2019
ohpnzasgbg(vcvbzrqvtw) = myrnymrcqf fgejwnxxxs (ggkhpuyqxh )
Phase 2
342
gsxiggfevf = tmfdjbjqmu rbcikdyzok (hlmiyaqnub, dbohgovytn - ologizvukl)
-
12 Mar 2019
(PLACEBO)
gsxiggfevf = ftvcjhcoro rbcikdyzok (hlmiyaqnub, peuwkvxvxm - jyupxcjvlv)
Phase 3
705
Placebo
ehqsdwytwi = ithsbcrwbt jkftjdxmzu (dqqtgxxpen, ktrhddfevt - lxskgrgeqe)
-
19 Dec 2018
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free